DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Tools I Use
Real-Time Market Scanner
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Recommended Platform
Professional Trading Workflow
Charts • Watchlists • Multi-broker tools
Built for active traders
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
$SPY daily chart — open the live Finviz viewStatic chart image; affiliate tracking is used only after a click.
Weekly Market Recap & Week Ahead: AI Selloff, Oil Shock and a Catalyst-Heavy Earnings Week — $SPY $QQQ $XBI
The July 13–17 tape delivered a sharp semiconductor reset, cooler inflation data, a renewed oil shock and resilient rotation below the headline indices. Next comes Alphabet, Tesla, Texas Instruments and Intel, plus AMD’s AI event, Farnborough, biotech data and a weekend FDA decision.
Weekend bridge: the cash market is closed, but the U.S.–Iran conflict escalated again overnight. Oil, Gulf infrastructure, the Strait of Hormuz and any retaliatory headlines are the first variables to reassess before Monday’s open.
What mattered most — and what matters next
- The leadership break was concentrated, not universal. Semiconductors and mega-cap technology drove the headline damage, while the equal-weight market, financials, industrials and energy showed better relative strength.
- Inflation looked cooler in the rear-view mirror. June CPI fell 0.4% month over month and core CPI rose 2.6% year over year; June PPI fell 0.3%. But the renewed jump in crude oil threatens to make those numbers feel stale quickly.
- AI spending becomes the market’s main earnings test. Alphabet’s Wednesday report is the first hyperscaler checkpoint after the chip rout. Texas Instruments and Intel will test whether high expectations across semiconductors still have fundamental support.
- Next week is event-rich despite a light U.S. macro calendar. Earnings, the ECB, AMD Advancing AI, Farnborough and biotech catalysts can create violent single-name and sector moves even if the broad indices remain range-bound.
- The cleanest risk map is cross-asset. Watch Brent and WTI, the U.S. 10-year yield, the dollar, semiconductor breadth and whether $SPY can stabilize without another round of forced selling in crowded AI names.
Top Stocks to Watch — catalyst, timing and confirmation trigger
This is an event map, not a buy list. The priority is to know why a ticker is on the screen, when the information arrives and what would confirm—or invalidate—the setup.
| Ticker | Timing | Catalyst | What matters most |
|---|---|---|---|
| $GOOGL Market mover | Wed, after close | Q2 earnings | 2026 AI capex, Google Cloud backlog conversion, Search resilience, Gemini timing and evidence that spending can produce durable returns. |
| $TSLA High volatility | Wed, after close | Q2 earnings | Automotive gross margin, robotaxi fleet expansion, new-market timing, deliveries, capex and cash generation. |
| $TXN Chip test | Wed, after close | Q2 earnings | Analog and embedded demand, industrial/auto inventory, pricing, free cash flow and whether the semiconductor correction has fundamental support. |
| $AMD AI event | Wed–Thu | Advancing AI 2026 | Product availability, performance per dollar, software ecosystem, customer adoption and credible shipment timing. Lisa Su’s keynote is Thu at 12:30 ET. |
| $INTC Chip test | Thu, after close | Q2 earnings | Server demand, gross margin, foundry milestones, capital intensity and whether the 2026 rally can withstand execution risk. |
| $RTX Defense | Thu, 7:30 ET | Q2 call + Farnborough | Commercial aerospace execution, engine remediation, defense backlog conversion, margins and any airshow order or program update. |
| $LMT / $NOC Defense | Tue–Thu | Earnings + Farnborough | Missile demand, classified programs, backlog quality, supply constraints and the distinction between new awards and previously announced funding. |
| $GEV Power | Wed, before open | Q2 earnings | Grid and turbine backlog, data-center power demand, order conversion, pricing and margin execution. |
| $KURA Clinical data | Fri, 3:05–3:45 ET | Updated FIT-001 Phase 1a data | Patient count, follow-up, response durability, prior therapies, safety and support for the randomized Phase 1b design. |
| $MNKD FDA | Sun, Jul 26 | FUROSCIX ReadyFlow PDUFA | Exact label, device-use language, launch readiness, reimbursement and Friday-to-Sunday binary gap risk. |
| $OTLK Near horizon | Wed, Jul 29 | LYTENAVA FDA decision | Manufacturing remediation, inspection status, launch funding, warrants, ATM capacity and cash runway. |
| $SPY / $QQQ / $SOXX / $XBI Confirmation | All week | Market and sector proxies | Whether semiconductor weakness remains concentrated, breadth improves, energy inflation spreads, and biotech can trade independently of mega-cap technology. |
From inflation relief to an AI valuation reset
The week began with investors waiting for inflation confirmation and ended with the Nasdaq under sustained pressure, Netflix down double digits after earnings and the semiconductor index more than 20% below its late-June high. The S&P 500 and Nasdaq posted a second consecutive weekly decline, but the tape was more nuanced than the headline numbers: eight of the eleven S&P sectors were positive during Thursday’s tech washout, and the equal-weight index held up much better than the cap-weighted benchmarks.
Monday — positioning before inflationRisk appetite was cautious as traders prepared for CPI, bank earnings and a dense corporate calendar. The key question was whether softer inflation could offset stretched AI positioning.
Tuesday — CPI delivered reliefJune headline CPI fell 0.4% month over month and slowed to 3.5% year over year. Core inflation eased to 2.6% year over year. The report lowered immediate rate-hike anxiety, though energy’s renewed climb quickly complicated the message.
Wednesday — PPI and ASML reinforced the split tapeProducer prices fell 0.3% in June. ASML posted €9.3 billion in quarterly sales, €2.9 billion in net income and raised its 2026 sales outlook, but the market increasingly demanded evidence that exceptional AI demand could justify exceptional valuations.
Thursday — semiconductors broke lowerSelling accelerated across memory, equipment and AI infrastructure names. Strong bank results and resilient non-tech sectors could not prevent a broad Nasdaq decline. The move looked like a crowded-position reset, but price damage became technically meaningful.
Friday — Netflix, oil and geopolitics added pressureNetflix fell roughly 11% after a softer outlook; oil jumped more than 4% as the U.S.–Iran conflict intensified. The S&P 500 lost 1.01%, the Nasdaq 1.4% and the Dow 0.77% in the final session.
Cooler domestic inflation met a fresh external inflation shock
June CPI
Headline CPI fell 0.4% MoM and slowed to 3.5% YoY. Core CPI rose 2.6% YoY, down from 2.9% in May. The near-term Fed message became less urgent.
June PPI
Final-demand PPI fell 0.3% MoM, the biggest decline in fourteen months. The 12-month rate remained elevated at 5.5%, so the report was relief, not an all-clear.
Retail sales and claims
June retail sales rose 0.2%; the core control-group-style signal was firmer. Initial claims fell to 208,000, the lowest since May, keeping the labor backdrop comparatively resilient.
Brent and WTI
Brent ended near $88.10 and WTI near $82.49, each up roughly 4.5% on Friday. A persistent move higher would feed back into inflation expectations, transport margins and Fed pricing.
U.S. 10-year yield
The 10-year finished around 4.55%, little changed on the week. That stability hid an important tension: cooler data pulls yields down, while oil and geopolitical risk can push inflation compensation higher.
Gold
Gold finished around $4,015 and lost more than 3% for the week. The decline despite geopolitical stress suggests positioning, real yields and dollar dynamics mattered more than a simple safe-haven narrative.
The macro contradiction to carry forward
The June CPI and PPI releases reduced the probability of an immediate Fed response, but both reports captured a period when energy prices were retreating. Markets now have to decide whether renewed Middle East escalation is temporary noise or the start of a second inflation impulse. With the next FOMC meeting on July 28–29, every move in oil and inflation expectations matters.
Where leadership weakened — and where money rotated
AI hardware and semiconductors
The PHLX Semiconductor Index closed more than 20% below its late-June record. Memory, equipment, networking and crowded AI winners were hit as investors questioned capex efficiency, peak margins and whether lower-cost Chinese models could change the economics of the buildout.
Next test: $GOOGL capex, $TXN demand commentary, $INTC server and foundry execution, and whether $AMD can reset the narrative at Advancing AI.
Broad market breadth
The cap-weighted indices looked weaker than the average stock. Financials, industrials and select cyclicals held up, while the equal-weight S&P remained near recent highs. A broadening market would be constructive; indiscriminate selling beyond technology would be a warning that the correction is becoming systemic.
Energy and defense
Oil producers benefited from the crude spike, while defense names remained tied to Middle East headlines and the expanding security agenda. Farnborough will put missiles, drones, autonomy, aircraft backlogs and supply constraints in the spotlight.
Biotech and healthcare
The sector delivered a dense mix of FDA decisions, M&A, financing and clinical-data setups. The lesson was familiar: science and corporate structure must be analyzed together. Approval does not eliminate launch, label, cash-runway or dilution risk.
The most consequential corporate stories
$ASML — strong quarter, higher outlook
Q2 sales reached €9.3 billion, net income €2.9 billion and EPS €7.59. ASML raised full-year 2026 net-sales guidance to €43–45 billion with a 54%–56% gross-margin range. It was one of the clearest pieces of fundamental support for AI infrastructure demand.
$NFLX — guidance reset
Revenue of $12.56 billion narrowly missed consensus and the third-quarter outlook disappointed. Shares fell roughly 11% Friday, reviving questions about engagement, disclosure and the competitive cost of attention.
Money-center banks — healthy start
Major banks benefited from stronger trading revenue and M&A advisory fees. The reports helped the financial sector absorb some of the rotation out of technology and suggested capital-markets activity remains supportive.
$TSM and the expectation problem
Strong operating results did not immunize the stock from the broader chip selloff. When positioning and valuation are extreme, “good” can be insufficient; guidance, capex returns and forward supply-demand commentary become the real catalyst.
Moonshot AI — the new fear
Chinese startup Moonshot unveiled a Kimi model it said could compete with leading U.S. systems. The market reaction was less about one model and more about the possibility that cheaper inference or training could weaken the assumed return on hyperscaler capex.
Space complex — post-IPO gravity
SpaceX and listed space names weakened further as momentum unwound. The group now needs execution—launch cadence, backlog conversion and credible government or commercial milestones—to replace price momentum as the primary support.
Approvals, M&A and dilution moved the sector
| Ticker | Event | What happened | Trading / diligence angle |
|---|---|---|---|
| $CELC | FDA approval | The FDA approved Revtorpyk (gedatolisib) for a defined HR-positive/HER2-negative advanced breast-cancer population. | Approval was followed by selling as investors assessed label breadth, discontinuations, launch timing and commercialization risk. A regulatory win is not the same as a frictionless launch. |
| $ATAI / $LLY | Acquisition | Lilly agreed to buy AtaiBeckley for $6.75 cash per share plus a nontransferable CVR worth up to $2.50. The structure implies $2.8 billion upfront and up to $1 billion contingent. | The spread now reflects closing risk and the probability-weighted value of the CVR, not simply the headline “up to $3.8 billion” figure. |
| $MRK | FDA approval | The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor for LDL cholesterol reduction in eligible adults. | A strategically important category expansion: oral administration could broaden adoption, but payer access, pricing and real-world persistence will determine commercial impact. |
| $JSPR | Merger + PIPE | Jasper completed its all-stock Kira acquisition and announced a roughly $132 million PIPE. Legacy Jasper holders are expected to own about 6.68% on a fully diluted, as-converted basis. | The financing is not the purchase price. Share count, ownership transfer, exchange compliance and reverse-split risk are central to the equity story. |
| $DBVT | ATM filing | DBV filed an at-the-market prospectus allowing up to $150 million of sales. | Capacity is not the same as immediate issuance, but the overhang matters. Watch cash needs, volume, prospectus supplements and actual share-count changes. |
| $OTLK | Resale registration | A July 17 S-3 registered 17,258,065 shares underlying investor and placement-agent warrants from the April financing. | This was not a fresh primary offering. The relevant variables are warrant exercise, proceeds, existing ATM capacity and the July 29 FDA decision. |
For the full rolling calendar, use the Merlintrader Catalyst Total Tracker and the Biotech Stocks Hub.
ASRS catalysts that can shape Monday’s biotech tape
ASRS 2026 closes on Saturday, July 18. At the stated publication time, the following presentations were still scheduled rather than incorporated as completed results. Any company slide deck or post-presentation release should be checked before interpreting Monday’s premarket reaction.
$BLTE — Phase 3 DRAGON
Belite Bio is scheduled to present Phase 3 DRAGON results for tinlarebant in Stargardt disease. Focus on the prespecified endpoint, effect size, sensitivity analyses, safety and whether the conference presentation adds information beyond prior disclosures.
$ANNX — ARCHER analysis
Annexon will discuss baseline characteristics associated with confirmed ≥15-letter BCVA loss in Phase 2 ARCHER. This is an important patient-selection and Phase 3 interpretation exercise, but it is not a new pivotal topline readout.
$FDMT — 4D-150 at two years
4DMT is scheduled to present two-year PRISM Phase 2b follow-up in wet AMD. This is the most clearly incremental Saturday dataset of the three: durability, supplemental-injection burden, visual acuity, anatomy and inflammation are the central variables.
Monday gap-risk rule: do not trade the headline alone. Compare the presentation with the prior dataset, check the evaluable population and follow-up cut, then separate true clinical change from conference repackaging.
Why Monday may begin before the earnings calendar
Iran renewed attacks on U.S.-aligned Gulf states after another night of U.S. strikes, with reported targets including military and critical infrastructure. The market transmission channel is straightforward: escalation can lift crude oil, shipping insurance and inflation expectations; higher inflation expectations can pressure bonds and duration-sensitive technology; defense and energy can outperform on a relative basis.
Escalation trigger
Confirmed disruption to Gulf production, desalination, ports, bases or shipping lanes—especially the Strait of Hormuz—would be materially different from headline-only risk.
Price confirmation
Watch Sunday futures, Brent and WTI gaps, tanker rates, the dollar and U.S. Treasury yields. Cross-asset confirmation matters more than social-media intensity.
De-escalation signal
Verified diplomatic movement, intact shipping flows and oil giving back Friday’s jump would reduce the probability of a persistent inflation impulse.
July 20–24, 2026 — day by day
The U.S. economic calendar is relatively light, but the company calendar is not. Times below are Eastern Time; Central European Summer Time is six hours ahead. Earnings dates can change, so confirm against company investor-relations pages before the event.
Monday, July 20Positioning day • Farnborough opens
10:00 ET
16:00 CEST
16:00 CEST
Conference Board Leading Economic Index — June
A softer LEI would reinforce the slowdown narrative, but the market may treat it as secondary unless oil or yields amplify the signal.
Farnborough International Airshow beginsCommercial aircraft orders, defense systems, drones, autonomy, supply chains and delivery schedules move into focus. Watch $BA, $RTX, $LMT, $NOC, $AVAV, $KTOS, $RCAT, $ONDS and the broader space-defense complex.
Earnings: $DPZ before the open; $STLD, $WRB, $ZION and others after the close.Tuesday, July 21Industrials, autos, banks and defense
Before / after market
No major top-tier U.S. macro release scheduled
The tape will be driven by earnings, oil and any weekend follow-through.
Before the open: $MMM, $SCHW, $DHR, $GM, $DHI, $HAL, $NOC, $GPC, $MRSH and $MSCI.After the close: $COF, $CB, $IBKR, $EQT and other financial or energy names. Autos, housing, industrial demand and consumer credit will supply useful read-throughs.
Wednesday, July 22The week’s AI stress test
BMO / AMC
AMD event day 1
AMD event day 1
Before the open: $GEV, $PM, $T, $CME, $PHM and $TEL.
After the close: $GOOGL, $TSLA, $TXN, $IBM, $NOW and $CSX.
What matters: Alphabet’s 2026 capex plan, Google Cloud backlog conversion, Search resilience, AI monetization and Gemini timing; Tesla’s automotive margins, deliveries, robotaxi expansion and capex; Texas Instruments’ analog/embedded demand, inventory and free-cash-flow trajectory.
AMD Advancing AI beginsInitial product and ecosystem updates can move $AMD and adjacent compute, networking, memory and server names even before the keynote.
Thursday, July 23Claims • ECB • AMD • Intel • defense
7:30–12:30 ET
13:30–18:30 CEST
13:30–18:30 CEST
7:30 ET — RTX Q2 call
Commercial aerospace execution, engine issues, defense backlog and margins will matter during Farnborough week.
8:30 ET — Initial jobless claimsConsensus is near 212,000 after 208,000. A sharp surprise would matter more than the small week-to-week change.
ECB rate decisionRelevant for the euro, global yields and multinational earnings translation.
12:30 ET / 18:30 CEST — AMD Advancing AI keynoteLisa Su is expected to cover the next AI infrastructure roadmap, architecture and developer ecosystem.
Earnings: $RTX, $TMO, $UNP, $BX, $LMT, $FCX, $CMCSA and $HON before the open; $INTC after the close. Intel’s server demand, gross margin, foundry milestones and capital intensity are the main semiconductor checkpoint.Friday, July 24PMIs • housing • biotech data • weekend FDA risk
9:45–10:00 ET
15:45–16:00 CEST
15:45–16:00 CEST
9:45 ET — S&P Global flash U.S. PMIs
The first July read on manufacturing and services. Prices-paid details will be especially important after the oil spike.
10:00 ET — June new home salesA test of mortgage-rate pressure, affordability and builder incentives.
Earnings: $AXP, $NEE, $VZ and $HCA.
3:05–3:45 ET — Kura Oncology data$KURA will present updated Phase 1a FIT-001 results for darlifarnib plus cabozantinib in advanced renal cell carcinoma at KCRS.
Weekend setup: $MNKD’s FUROSCIX ReadyFlow autoinjector sNDA has a July 26 PDUFA date. Friday’s close can therefore carry binary-event gap risk into Sunday.The reports with the broadest market read-through
| Date | Companies | Primary read-through | Risk question |
|---|---|---|---|
| Mon Jul 20 | $DPZ, $STLD, $WRB, $ZION | Consumer demand, steel pricing, insurance, regional banks | Can cyclicals keep absorbing rotation out of mega-cap tech? |
| Tue Jul 21 | $MMM, $SCHW, $DHR, $GM, $DHI, $HAL, $NOC, $COF, $CB | Industrial activity, autos, housing, oil services, defense, credit | Are margins holding as energy and financing costs rise? |
| Wed Jul 22 | $GOOGL, $TSLA, $TXN, $IBM, $NOW, $GEV, $PM, $T | AI capex, cloud, EVs, analog chips, enterprise software, power demand | Will fundamental guidance validate the AI and electrification premium? |
| Thu Jul 23 | $RTX, $TMO, $LMT, $HON, $FCX, $CMCSA, $INTC | Aerospace, defense, life-science tools, copper, media, semiconductors | Does the chip rout stabilize, and can defense backlog convert to margin? |
| Fri Jul 24 | $AXP, $VZ, $NEE, $HCA | High-end consumer, telecom, power demand, healthcare utilization | Is the consumer resilient enough to offset higher rates and energy costs? |
Wednesday is the fulcrum. A constructive Alphabet capex and cloud message could calm the AI complex; a cautious capex or monetization signal would reinforce the argument that hardware expectations ran ahead of returns. Tesla and Texas Instruments add two separate tests of high-expectation growth.
Biotech, AI, aerospace and the near-horizon wall
| Date | Ticker / theme | Event | What to verify |
|---|---|---|---|
| Jul 20–24 | Aerospace & defense | Farnborough International Airshow | Order quality versus headline quantity; delivery dates; supplier constraints; defense awards; drone and autonomy programs. |
| Jul 22–23 | $AMD / AI infrastructure | AMD Advancing AI 2026 | Product availability, performance-per-dollar, ecosystem adoption, hyperscaler commitments and credible shipment timing. |
| Jul 24 | $KURA | Updated long-term Phase 1a FIT-001 data in cabozantinib-naïve advanced clear-cell RCC | Patient count, follow-up, response durability, prior therapy mix, safety and how the dataset supports the randomized Phase 1b design. |
| Jul 26 | $MNKD | FUROSCIX ReadyFlow autoinjector sNDA PDUFA | Exact label, device usability language, launch readiness, reimbursement and whether approval expands the addressable setting. |
| Jul 29 | $OTLK | LYTENAVA FDA decision | Manufacturing remediation, inspection status, label, launch funding and the interaction between warrants, ATM capacity and cash runway. |
| Jul 29 | $CAPR | FDA advisory committee for deramiocel | Briefing documents, efficacy consistency, missing-data sensitivity, safety, manufacturing and the exact voting question. |
| Jul 30 | $REPL | FDA advisory committee for RP1 | Control-arm interpretation, treatment effect, safety, CMC and whether panel language changes perceived approval probability. |
Timing discipline: July 29–30 events are outside the upcoming trading week but close enough to influence positioning, financing and volatility during July 20–24.
Three paths for the coming week
Bull case
Oil gives back its geopolitical premium, yields remain contained, Alphabet validates AI capex returns, and semiconductor breadth stabilizes. Rotation broadens without turning into forced deleveraging.
Base case
Choppy, two-way tape. Technology remains volatile, but financials, industrials, energy and healthcare absorb flows. Earnings create large single-name gaps while $SPY holds a broad range.
Bear case
Gulf escalation pushes oil and yields higher, Alphabet or Intel disappoints, and selling spreads from semiconductors into the equal-weight market. Correlations rise and defensive positioning dominates.
Practical confirmation checklist
Broad market
$SPY, $QQQ, $IWM, equal-weight S&P and advance/decline breadth. The question is whether weakness stays concentrated or becomes market-wide.
AI / semiconductors
$SOXX, $SMH, $NVDA, $AMD, $INTC, $TXN, $ASML and $TSM. Look for higher lows, improving breadth and a positive response to genuinely strong guidance.
Cross-asset
Brent, WTI, U.S. 10-year yield, dollar index, gold and VIX. A simultaneous rise in oil, yields and volatility is the most difficult combination for long-duration equities.
Defense / aerospace
$RTX, $LMT, $NOC, $BA, $AVAV, $KTOS, $RCAT, $ONDS and $RKLB. Separate confirmed contracts and deliveries from nonbinding show headlines.
Biotech
$KURA, $MNKD, $OTLK, $CAPR and $REPL. Read primary documents, identify exact event timing and model dilution before treating a catalyst as a directional thesis.
The market is moving from a macro week into a proof week
Last week’s cooler CPI and PPI reduced one immediate threat, but oil and geopolitics introduced another. The semiconductor correction has already moved beyond a routine one-day wobble, yet the resilience of the equal-weight market shows that investors have not abandoned risk wholesale.
That makes the coming week less about forecasting one index close and more about measuring confirmation. Do hyperscalers defend AI spending with credible returns? Do chip companies support the demand narrative? Does oil retain its war premium? Can industrials, financials and healthcare keep broadening the tape? And in biotech, do primary data and FDA documents support the social-media version of each catalyst?
The most important discipline: define what would confirm or invalidate each setup before the event. In a tape this headline-sensitive, a good story without timing, liquidity and risk controls is not a plan.
Primary sources and further reading
- Reuters — Wall Street Week Ahead
- Reuters — Iran and Gulf escalation
- U.S. BLS — June 2026 CPI
- U.S. BLS — June 2026 PPI
- U.S. Census Bureau — release calendar
- Charles Schwab — market update and earnings calendar
- Alphabet Investor Relations
- Tesla Investor Relations
- RTX Investor Relations
- AMD — Advancing AI 2026
- Farnborough International Airshow
- Kura Oncology — July 24 KCRS presentation
- Belite Bio — Phase 3 DRAGON at ASRS
- ASRS — July 18 scientific program
- 4DMT — 4D-150 PRISM presentation
- FDA — first oral PCSK9 inhibitor
- SEC — Outlook Therapeutics S-3
- Merlintrader — Jasper/Kira merger analysis
- Merlintrader — Space, Defense & AI Hub
- Merlintrader — MannKind Stock Hub
- Merlintrader — Outlook Therapeutics Stock Hub
Market levels and weekly changes are based on the Friday, July 17, 2026 close. Event schedules and consensus estimates can change; confirm with the organizer, regulator or company investor-relations page.
Follow the live catalyst flow
Weekly reports build the map. For intraday updates, filings, biotech catalysts and schedule changes, follow Merlintrader on Telegram.
Join @merlintrader_eu on Telegram